Regeneron Pharmaceuticals (Nasdaq: REGN) will supply an additional 1.25M treatment courses of an antibody cocktail composed of casirivimab and imdevimab to the U.S. government under a potential $2.63B agreement with the departments of Defense and Health and Human Services.
DOD said Tuesday the biotechnology company is scheduled to deliver the medicines during the first half of this year to be used as treatment for high-risk and non-hospitalized COVID-19 patients as part of Operation Warp Speed, the federal government’s vaccination initiative with the private sector.
The Food and Drug Administration granted emergency use authorization to Regeneron’s antibody combination drug in November 2020.
The agreement with the company will bring the total number of casirivimab-imdevimab treatment course orders from both DOD and HHS to more than 1.5M, according to the Pentagon.
DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense partnered with HHS’ Biomedical Advanced Research and Development Authority and the U.S. Army for the contracting process.
HHS awarded $2.05B in contracts to Novavax and Regeneron in July to expedite COVID-19 drug production work. The latter company is working to deliver an initial 300K doses to health departments at the state and territorial levels.